Core Viewpoint - The company, Gui Faxiang, anticipates a negative net profit for the fiscal year 2025, projecting a range between -26 million to -23 million yuan, a significant decline from the previous year's net profit of 27.073 million yuan [1] Financial Performance - The expected net profit excluding non-recurring gains and losses is projected to be between -27 million to -24 million yuan, compared to 24.4191 million yuan in the same period last year [1] - Overall operating revenue has decreased due to declining sales and production, leading to increased fixed manufacturing costs and higher unit costs [1] Market Conditions - The decline in revenue is attributed to insufficient consumer demand and purchasing power, as well as intensified industry competition [1] - While revenue from e-commerce channels has shown growth, it has not been sufficient to offset the decline in traditional channel revenues [1] Product Performance - There has been a decrease in the sales revenue proportion of gift products, contributing to an overall decline in gross profit [1]

易事特公告，预计2025年度净利润为2400万元～3500万元，同比下降81.50%～87.32%。2025年，公司 聚焦数字能源主业，紧抓行业发展机遇，管理层加大市场拓展力度，推动整体营业收入实现稳步增长。 但受行业竞争加剧、产品销售结构调整、内卷态势凸显影响，公司整体毛利率承压下行，导致利润下 滑。 ...

康众医疗公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比，将减少2265.27万 元到2665.27万元，同比减少128.32%到150.98%，实现归属于母公司所有者的净利润为负，预计在-900 万元到-500万元之间。 ...

*ST波导公告，预计2025年年度实现归属于母公司所有者的净利润为600万元到800万元。公司预计2025 年年度实现营业收入为4.5亿元到4.9亿元，扣除与主营业务无关的业务收入和不具备商业实质的收入后 的营业收入为4.2亿元到4.6亿元。 ...

万达电影公告，预计2025年度净利润为4.8亿元～5.5亿元，上年同期为-9.4亿元。2025年，公司依托超 过700家直营影院体系和8000万线上会员优势，凭借高效的经营管理能力与"五星级影城"服务品质，进 一步夯实行业领先地位。报告期内，公司实现票房76.78亿元(含服务费)，同比增长18.53%，观影人次 1.63亿，同比增长14.76%，市场份额连续17年稳居行业首位。 ...

Core Insights - The National Press and Publication Administration announced the approval of 182 game licenses in January 2026, including 177 domestic and 5 imported games, maintaining a relatively high issuance level [1] - In 2025, a total of 1,771 game licenses were issued, significantly surpassing the 1,416 licenses in 2024, marking the highest issuance since 2019 [1] - Major companies such as Tencent, NetEase, and others received approvals for key products, including Tencent's "Rainbow Six: Siege" and NetEase's "Yao Yao Chess" [1] Group 1 - The January 2026 approvals included significant titles from major gaming companies, indicating a robust market for both domestic and imported games [1] - Tencent's "Rainbow Six: Siege" is a tactical shooter developed by Ubisoft and is part of Tencent's strategy to enhance its gaming portfolio through partnerships [2][4] - The approval of "Angry Birds: Classic Return" and "Angry Birds: Dream Blast" by Kingsoft's subsidiary marks a strategic partnership aimed at reintroducing the franchise to the Chinese market [4] Group 2 - Tencent's investment of €1.16 billion in Ubisoft's subsidiary Vantage Studios grants it a 26.32% stake, integrating key IPs like "Assassin's Creed" and "Rainbow Six," which helps alleviate Ubisoft's financial pressure [4] - The "Rainbow Six: Siege" team is focused on creating a fair competitive environment and enhancing local services for the Chinese market, indicating a commitment to localization and community engagement [4] - Kingsoft's strategic partnership with Rovio aims to facilitate the exclusive distribution and operation of the "Angry Birds" series in China, highlighting the importance of collaboration in the gaming industry [4]

天威视讯公告，公司与深圳市幸福健康产业(集团)有限公司于2026年1月27日签署了《战略合作框架协 议》。根据协议，双方将在智慧康养服务领域开展合作，公司为幸福健康集团提供全场景智慧网络融合 解决方案及家庭用户服务能力，幸福健康集团为公司提供线下服务场景及行业资源优势。协议有效期为 3年，到期后可自动延续。 ...

同济科技公告，2025年10月至12月，公司新签施工合同额约人民币11.48亿元，较上年同期增长 85.46%；其中超过1000万元以上的施工合同11个，合同金额累计11.1亿元。2025年1-12月，公司新签施 工合同额合计人民币39.78亿元，较上年同期减少2.00%。 ...

Core Viewpoint - The announcement indicates that the drug candidate BPI-572270, developed by the company's wholly-owned subsidiary Jingyao Biotech, has received approval from the National Medical Products Administration for clinical trials in patients with advanced malignant solid tumors [1] Group 1: Drug Development - BPI-572270 is a new molecular entity that the company has independently developed and holds complete intellectual property rights [1] - It is characterized as a novel and potent pan-RAS non-degradable molecular glue inhibitor [1] Group 2: Mechanism of Action - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated mutant RAS proteins, leading to conformational changes in RAS proteins [1] - This process prevents RAS proteins from binding to downstream signaling proteins, such as cRAF, thereby blocking the MAPK signaling pathways responsible for tumor growth [1]

*ST金比公告，预计2025年度净利润为负值。预计利润总额为-2亿元至-1.4亿元，同比下降297.83%至 382.61%；归属于上市公司股东的净利润为-1.9亿元至-1.3亿元，同比下降349.28%至464.33%；扣除非经 常性损益后的净利润为-1.2亿元至-8000万元，同比下降76.53%至164.80%；基本每股收益为-0.54元 至-0.37元；营业收入为3.5亿元至3.8亿元，上年同期为2.25亿元。 ...